Total Payments
$752.15
2024 Payments
$27.74
Companies
9
Transactions
31
Medicare Patients
13,448
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$610.17 (81.1%)
Education$141.98 (18.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $610.17 | 29 | 81.1% |
| Education | $141.98 | 2 | 18.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $534.80 | 21 | $0 (2022) |
| Janssen Biotech, Inc. | $68.97 | 3 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $30.94 | 1 | $0 (2018) |
| Ferring Pharmaceuticals Inc. | $27.74 | 1 | $0 (2024) |
| PRN Medical Services, LLC | $20.25 | 1 | $0 (2017) |
| Avadel Specialty Pharmaceuticals, LLC | $19.24 | 1 | $0 (2018) |
| AbbVie, Inc. | $19.03 | 1 | $0 (2018) |
| Coloplast Corp | $15.80 | 1 | $0 (2019) |
| TOLMAR Pharmaceuticals, Inc. | $15.38 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27.74 | 1 | Ferring Pharmaceuticals Inc. ($27.74) |
| 2022 | $51.99 | 1 | Astellas Pharma US Inc ($51.99) |
| 2020 | $23.14 | 1 | Astellas Pharma US Inc ($23.14) |
| 2019 | $178.44 | 5 | Astellas Pharma US Inc ($162.64) |
| 2018 | $276.79 | 13 | Astellas Pharma US Inc ($123.23) |
| 2017 | $194.05 | 10 | Astellas Pharma US Inc ($173.80) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $27.74 | General |
| Category: ONCOLOGY | ||||||
| 10/13/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $51.99 | General |
| 02/05/2020 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2019 | Coloplast Corp | SPEEDICATH (Device) | Food and Beverage | Cash or cash equivalent | $15.80 | General |
| Category: CONTINENCE | ||||||
| 09/23/2019 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: ONCOLOGY | ||||||
| 07/08/2019 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: UROLOGY | ||||||
| 05/20/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $89.99 | General |
| 01/15/2019 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: UROLOGY | ||||||
| 12/07/2018 | TOLMAR Pharmaceuticals, Inc. | ELIGARD (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Prostate Cancer | ||||||
| 11/13/2018 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: UROLOGY | ||||||
| 10/03/2018 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: UROLOGY | ||||||
| 09/11/2018 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $35.20 | General |
| Category: Oncology | ||||||
| 07/26/2018 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2018 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Oncology | ||||||
| 04/12/2018 | Avadel Specialty Pharmaceuticals, LLC | Noctiva (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: Urology | ||||||
| 04/05/2018 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Oncology | ||||||
| 03/19/2018 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: UROLOGY | ||||||
| 03/08/2018 | Janssen Pharmaceuticals, Inc | ZYTIGA (Drug) | Food and Beverage | In-kind items and services | $30.94 | General |
| Category: Oncology | ||||||
| 02/27/2018 | AbbVie, Inc. | Lupron (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: Endocrinology | ||||||
| 02/02/2018 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: UROLOGY | ||||||
| 01/30/2018 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: UROLOGY | ||||||
| 11/27/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Xtandi | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Urology | ||||||
| 09/05/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Xtandi | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Urology | ||||||
| 08/08/2017 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Urology | ||||||
| 07/10/2017 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Urology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 3,345 | 4,040 | $1.8M | $275,896 |
| 2022 | 26 | 3,499 | 4,479 | $1.8M | $314,674 |
| 2021 | 27 | 3,675 | 4,621 | $1.7M | $318,505 |
| 2020 | 25 | 2,929 | 3,581 | $1.3M | $236,156 |
Total Patients
13,448
Total Services
16,721
Medicare Billing
$1.1M
Procedure Codes
102
All Medicare Procedures & Services
102 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 679 | 839 | $356,575 | $60,444 | 17.0% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 169 | 207 | $144,900 | $43,608 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 252 | 301 | $135,450 | $31,396 | 23.2% |
| 50590 | Shock wave crushing of kidney stones | Facility | 2023 | 40 | 45 | $153,000 | $21,708 | 14.2% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 214 | 229 | $131,675 | $21,436 | 16.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 243 | 341 | $127,875 | $16,369 | 12.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 107 | 107 | $56,175 | $14,668 | 26.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 13 | 69 | $43,042 | $9,464 | 22.0% |
| 52281 | Dilation of urethra using an endoscope | Office | 2023 | 28 | 31 | $29,450 | $8,956 | 30.4% |
| 76775 | Limited ultrasound scan behind abdominal cavity | Office | 2023 | 123 | 139 | $72,280 | $7,180 | 9.9% |
| 51729 | Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | Office | 2023 | 20 | 20 | $35,000 | $7,128 | 20.4% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 578 | 691 | $224,575 | $6,521 | 2.9% |
| 51741 | Electronic assessment of bladder emptying | Office | 2023 | 421 | 504 | $163,800 | $5,637 | 3.4% |
| 51797 | Insertion of device into abdomen with pressure and urine flow rate study | Office | 2023 | 21 | 21 | $15,225 | $3,786 | 24.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 39 | 39 | $13,650 | $3,711 | 27.2% |
| 55700 | Biopsy of prostate gland | Office | 2023 | 17 | 17 | $11,900 | $3,688 | 31.0% |
| 51720 | Instillation of anti-cancer drug into bladder | Office | 2023 | 13 | 48 | $20,400 | $3,633 | 17.8% |
| 76872 | Ultrasound scan of pelvic region through rectum | Office | 2023 | 15 | 15 | $7,875 | $1,914 | 24.3% |
| 53660 | Initial dilation of urethra in female | Office | 2023 | 15 | 19 | $4,275 | $1,189 | 27.8% |
| 76942 | Ultrasonic guidance for needle placement | Office | 2023 | 19 | 19 | $10,450 | $993.13 | 9.5% |
| 81002 | Urinalysis, manual test | Office | 2023 | 266 | 276 | $4,140 | $941.16 | 22.7% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 23 | $2,070 | $687.28 | 33.2% |
| 51784 | Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | Office | 2023 | 21 | 21 | $10,500 | $599.76 | 5.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 19 | 19 | $2,375 | $239.40 | 10.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 737 | 969 | $284,425 | $69,907 | 24.6% |
About Dr. Ned Saltzman, M.D
Dr. Ned Saltzman, M.D is a Urology healthcare provider based in Newton, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1891784112.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ned Saltzman, M.D has received a total of $752.15 in payments from pharmaceutical and medical device companies, with $27.74 received in 2024. These payments were reported across 31 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($610.17).
As a Medicare-enrolled provider, Saltzman has provided services to 13,448 Medicare beneficiaries, totaling 16,721 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 102 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Newton, MA
- Active Since 10/19/2005
- Last Updated 02/26/2009
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1891784112
Products in Payments
- Myrbetriq (Drug) $169.42
- MYRBETRIQ (Drug) $150.96
- Erleada (Drug) $68.97
- XTANDI (Drug) $68.06
- SPEEDICATH (Device) $36.05
- ZYTIGA (Drug) $30.94
- ADSTILADRIN (Biological) $27.74
- Noctiva (Drug) $19.24
- Lupron (Drug) $19.03
- ELIGARD (Drug) $15.38
- Xtandi (Drug) $4.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.